Research Article

Assessing the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Stage I Non-Small-Cell Lung Cancer with Complete Resection

Table 3

Univariate and multivariate Cox regression analyses of PFS and OS.

VariablesPFSOS
UnivariateMultivariateUnivariateMultivariate
HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)

Age (≥65 vs.<65)0.782 (0.483–1.268)0.3192.258 (1.011–5.040)0.0470.621 (0189–2.035)0.431
Gender (male vs. female)1.944 (1.181–3.200)0.0091.984 (0.927–4.246)0.0780.420 (0.188–0.937)0.0112.722 (0.568–13.045)0.210
Smoking history (cur/for vs. never)1.741 (1.078–2.813)0.0231.129 (0.515–2.475)0.7622.382 (1.067–5.318)0.0341.075 (0.267–4.331)0.919
Histologic type (squamous vs. adenocarcinoma)0.261 (0.113–0.607)0.0021.131 (0.489–2.620)0.5320.164 (0.069–0.391)0.0010.281 (0.059–1.337)0.111
Stage (IB vs. IA1 + IA2)2.067 (1.191–3.586)0.0101.590 (0.826–3.058)0.3492.463 (1.001–6.063)0.0411.928 (0.530–7.009)0.319
Differentiation (poor vs. well)1.513 (1.148–1.993)0.0020.669 (0.313–1.429)0.5783.918 (1.542–9.956)0.0041.122 (0.308–4.087)0.862
Lymphovascular invasion (present vs. absent)1.948 (1.138–3.333)0.0152.100 (1.090–4.043)0.0271.105 (0.413–2.961)0.842
Visceral pleural invasion (absent vs. present)0.969 (0.480–1.957)0.9300.556 (0.131–2.364)0.427
Tumor location (upper vs. lower)1.476 (0.851–2.562)0.1663.220 (1.391–7.453)0.0062.114 (0.765–5.843)0.149
Chemotherapy (no vs. yes)1.754 (0.955–3.222)0.0701.681 (0.720–3.929)0.230
CEA (high vs. low)3.895 (2.358–6.435)0.0012.953 (1.637–5.329)0.0015.004 (2.206–11.351)0.0013.995 (1.377–11.593)0.011
CYFRA211 (high vs. low)2.160 (1.306–3.571)0.0031.795 (0.879–3.664)0.1082.192 (0.929–5.172)0.073
RDW-SD (high vs. low)3.003 (1.863–4.841)0.0012.570 (1.458–4.528)0.0015.110 (2.234–11.686)0.0014.638 (1.6614–13.326)0.004
LDH (high vs. low)2.009 (1.236–3.260.0051.622 (0.904–2.912)0.1052.385 (1.069–5.325)0.0341.810 (0.634–5.168)0.268
NLR (high vs. low)1.612 (0.929–2.800)0.0904.839 (2.172–10.780)0.0013.208 (1.243–8.277)0.016